Asset
REVUMENIB SESQUIFUMARATE
SYNDAX PHARMACEUTICALS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06226571 | phase1 | active_not_recruiting | 2024-05-21 | 2027-02-01 | Syndax Pharmaceuticals | A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias |
FDA applications (0)
This company has no applications containing this asset.